Aptose TUSCANY trial: TUS+VEN+AZA triplet shows CRs, MRD negativity in high-risk AML

Aptose Biosciences Inc.

Four patients at 40 mg TUS+VEN+AZA: three achieved CR/CRi and MRD-negative, including a TP53-mutated/CK AML patient.
Three patients at 80 mg TUS+VEN+AZA: all had blast reductions meeting CR/CRi criteria in Cycle 1; no DLTs reported.
No dose-limiting toxicities across both cohorts; safety profile favorable for the triplet combination.
Enrollment target of 18–24 patients by mid-late 2025; additional data releases expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.